[go: up one dir, main page]

WO2011066980A3 - Formes de dose orale avec risque réduit d'abus de médicaments - Google Patents

Formes de dose orale avec risque réduit d'abus de médicaments Download PDF

Info

Publication number
WO2011066980A3
WO2011066980A3 PCT/EP2010/007340 EP2010007340W WO2011066980A3 WO 2011066980 A3 WO2011066980 A3 WO 2011066980A3 EP 2010007340 W EP2010007340 W EP 2010007340W WO 2011066980 A3 WO2011066980 A3 WO 2011066980A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral dosage
dosage form
drug abuse
reduced potential
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/007340
Other languages
English (en)
Other versions
WO2011066980A2 (fr
Inventor
Lars Holger Hermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011066980A2 publication Critical patent/WO2011066980A2/fr
Publication of WO2011066980A3 publication Critical patent/WO2011066980A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une forme de dose orale présentant un risque réduit d'abus de médicament qui comporte (a) au moins un composé actif pharmaceutique contenant une amine ou du sel ou solvate de celui-ci, (b) au moins un acide organique faible ou sel de celui-ci, qui forme un précipité insoluble avec le composant (a) dans un environnement aqueux à un pH d'au moins 5, et (c) au moins un agent basifiant dans une quantité appropriée pour obtenir un pH d'au moins 5 dans l'environnement de la forme de dose orale lorsqu'elle est dissoute. Selon l'invention, ladite au moins une partie de la forme de dose orale est formulée pour être libérée immédiatement et les composants (b) et (c) sont principalement contenus dans cette partie, et une autre partie de la forme de dose orale est formulée pour une libération prolongée et contient au moins la majorité du composant (a).
PCT/EP2010/007340 2009-12-04 2010-12-03 Formes de dose orale avec risque réduit d'abus de médicaments Ceased WO2011066980A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015063.2 2009-12-04
EP09015063 2009-12-04

Publications (2)

Publication Number Publication Date
WO2011066980A2 WO2011066980A2 (fr) 2011-06-09
WO2011066980A3 true WO2011066980A3 (fr) 2011-10-20

Family

ID=42169038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/007340 Ceased WO2011066980A2 (fr) 2009-12-04 2010-12-03 Formes de dose orale avec risque réduit d'abus de médicaments

Country Status (1)

Country Link
WO (1) WO2011066980A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356111B (es) 2012-04-18 2018-05-15 SpecGx LLC Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
WO2014145195A1 (fr) 2013-03-15 2014-09-18 Cerovene, Inc. Compositions pharmaceutiques comprenant un composant dépendant du ph et un agent d'augmentation du ph
JP6255474B2 (ja) 2013-03-15 2017-12-27 マリンクロッド エルエルシー 機能的割線を有する即時放出用の乱用抑止性固体剤形
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (fr) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération prolongée
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
AU2015274936B2 (en) 2014-06-09 2018-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
US11617712B2 (en) 2014-07-03 2023-04-04 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
EP3169316A4 (fr) * 2014-07-15 2018-01-24 Isa Odidi Compositions et procédés pour réduire une surdose
CA2910865C (fr) 2014-07-15 2016-11-29 Isa Odidi Compositions et methodes destines a reduire les surdoses
EP3169315B1 (fr) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
US20170157055A1 (en) * 2014-09-27 2017-06-08 Jayendrakumar Dasharathlal Patel Pharmaceutical abuse deterrent composition
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
MX2021002459A (es) 2018-09-25 2021-04-29 SpecGx LLC Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
EP4419085A4 (fr) * 2021-10-18 2025-08-20 Purdue Research Foundation Formulations anti-abus à base de nanoparticules et leurs procédés de fabrication et d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US20040234608A1 (en) * 2000-06-23 2004-11-25 Moshe Fleshner-Barak Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US20040234608A1 (en) * 2000-06-23 2004-11-25 Moshe Fleshner-Barak Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Also Published As

Publication number Publication date
WO2011066980A2 (fr) 2011-06-09

Similar Documents

Publication Publication Date Title
WO2011066980A3 (fr) Formes de dose orale avec risque réduit d'abus de médicaments
WO2011012816A3 (fr) Formulation pharmaceutique
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
WO2008057802A3 (fr) Compositions comprenant des agents d'inhibition de la pompe à protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procédés d'utilisation
WO2010136474A3 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
TW200833663A (en) Therapeutic agents
WO2010150995A3 (fr) Compositions de traitement de la dépendance aux drogues et d'amélioration du comportement lié aux dépendances
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2008143240A1 (fr) Préparation orale renfermant un acide organique spécifique et procédé d'amélioration de la propriété d'élution et de la stabilité chimique de la préparation orale
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
EP2196206B8 (fr) Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif
IL266097A (en) Citric acid acid salt of (R)-5-((E)-2-(pyrrolidine-3-yl)vinyl)pyrimidine, a pharmaceutical preparation containing the salt, use of the salt in the production of a medicine, salt for use, and method of production
WO2008003050A3 (fr) Formulations de nitrate de gallium
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
EP2077111A4 (fr) Agent antidépresseur
WO2007097888A3 (fr) Compositions de sel de fluoroquinolone et d'acide carboxylique
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008068299A3 (fr) Sel de bromhydrate d'un composé anti-vih
WO2009016069A3 (fr) Composition pharmaceutique liquide stable à base de trazodone
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
WO2007080401A8 (fr) Dérivés de triazoloanilinopyrimidine pouvant être employés en tant qu'agents antiviraux
WO2007098967A3 (fr) Composés ciblant les récepteurs sigma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810755

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10810755

Country of ref document: EP

Kind code of ref document: A2